Yoshino Matsuo on Muck Rack

Yoshino Matsuo

As seen in: MDPI, International Journal of Cardiology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yoshino

Contact Yoshino, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Development of a Non-Peptide Angiotensin II Type 1 Receptor Ligand by Structural Modification of Olmesartan as a Biased Agonist

|
By Yoshino Matsuo, Yasunori Suematsu, Hidetaka Morita, Shin-ichiro Miura
| MDPI
Open AccessArticle by 1, 1, 1 and 1,2,* 1 Department of Cardiology, Fukuoka University School of Medicine, Fukuoka 814-0180, Japan 2 Department of Internal Medicine, Fukuoka University Nishijin Hospital, Fukuoka 814-8522, Japan * Author to whom correspondence should be addressed.
Open in Who Shared Issue with article?

Anti-atherosclerotic effects of an improved apolipoprotein A-I mimetic peptide

|
By Yasunori Suematsu, Emi Kawachi, Yoshiaki Idemoto, Yoshino Matsuo
| International Journal of Cardiology Verified
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 A. Amino acid alignment in ApoA-I mimetics. B. % Cholesterol efflux using BSA, ApoA-I, FAMP and i-FAMPs. A172 cells were stimulated with 5 μmol/L of T0901317 and 9-cis-retinoic acid, and then 20 μg/ml of ApoA-I or each mimetic peptide was incubated with efflux medium. *p < 0.01 vs. FAMP (n = 9 each group). C.
Open in Who Shared Issue with article?
See all 2 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified